p53无表型在尿路上皮原位癌中是「阳性结果」
研究纳入22例患者的25个尿路上皮原位癌(CIS)标本,均显示p53无表型(完全不着色),其中21例通过NGS质控的病例100%检出至少1个TP53突变(多为无义或移码突变)。3例多时间点样本共享TP53突变支持克隆性,2例后期出现额外独特突变提示瘤内异质性和/或时间克隆演化。p53无表型应视为CIS的异常(支持性)结果,与p53强弥漫着色类似。
要点
- 尿路上皮CIS中p53无表型(完全不着色)应判读为异常/突变型结果,而非阴性。
- p53无表型CIS病例经NGS质控者100%检出TP53突变,多为无义或移码突变。
- 多时间点样本共享TP53突变支持克隆性,后期额外突变提示异质性与克隆演化。
核心结论
- p53无表型在尿路上皮CIS中代表异常结果,分子分析证实存在TP53突变且复杂度高于既往认识。
- 应像p53强弥漫着色一样,将p53无表型视为生物学支持性结果,并可能需制定p53报告共识(野生型 vs 异常/突变型)。
研究设计与样本
- 从22例患者(16男6女,年龄52-85岁,平均69.6岁)中选取25个H&E诊断的尿路上皮CIS且p53无表型的病例。
- 每例选一个代表性组织块行下一代DNA测序(NGS)。
主要发现
- 21例通过NGS质控的病例全部(100%)检出至少1个TP53突变,多数为无义或移码突变。
- 3例检出2个TP53突变,3例检出3个TP53突变。
- 3例有多时间点样本的患者在2个不同时间点共享1个或多个TP53突变,提示时间上不同病灶的克隆性。
- 2例患者在较晚时间点出现额外的独特TP53突变,提示瘤内异质性和/或时间克隆演化。
- 多数病例形态为大细胞多形性模式。
关键数值与推荐
- p53无表型定义为完全不着色,在尿路上皮CIS中应判读为异常/突变型结果。
- 多数通过质控的p53无表型CIS病例(21/21,100%)检出TP53突变,支持该判读。
临床怎么用
- 尿路上皮CIS多数仍为H&E诊断,p53免疫染色可用于部分疑难病例的辅助诊断。
- 遇到p53完全不着色时,应报告为异常/突变型(支持性结果),避免误判为阴性或野生型。
局限性
- 样本量较小(22例患者、25个CIS标本),仅21例通过NGS质控。
- 原文未报告NGS panel覆盖范围、突变等位基因频率及随访临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concept of a "p53 null phenotype" (complete loss of staining) is well-recognized in the gynecologic pathology literature, implicitly reflecting that this staining pattern represents a TP53 mutation. However, in the genitourinary pathology literature, a p53 null phenotype has only been addressed regarding the prognosis of invasive urothelial carcinoma, and not as a diagnostic biomarker for urothelial carcinoma in situ (CIS). Herein, 25 cases of urothelial carcinoma in situ [diagnoses made on hematoxylin and eosin (H&E) stained sections] showing null pattern p53 staining were retrieved from 22 different patients (16 males and 6 females, age range 52-85 years; average 69.6 years), most commonly showing large cell pleomorphic pattern morphology. One representative tissue block per case was selected for next-generation DNA sequencing (NGS). All 21 cases (100%) passing quality control for NGS showed at least 1 TP53 mutation (majority nonsense or frameshift mutations), including 3 cases with 2 mutations and 3 cases with 3 mutations. Three patients with multiple available samples harbored 1 or more shared TP53 mutations at 2 different time points, indicating clonality of the temporally distinct lesions. Additionally, 2 patients had an additional unique TP53 mutation at a later time point, suggesting intratumoral heterogeneity and/or temporal clonal evolution. While urothelial CIS remains an H&E diagnosis in most cases, a p53 immunostain may be useful in a subset of challenging cases. This study demonstrates that a p53 null phenotype represents an aberrant result in urothelial CIS with supportive molecular analysis showing a previously unknown level of complexity for TP53 mutations among these noninvasive lesions. Adequate recognition of the p53 null phenotype as a "biologically supportive result", similar to strong and diffuse staining with p53, is important and may warrant a formal consensus statement for recommended p53 reporting (i.e., "wild type" versus "aberrant or mutant").
引用
- Sangoi AR, Chan E, Abdulfatah E, et al. p53 null phenotype is a "positive result" in urothelial carcinoma in situ. Mod Pathol. 2022. PMID: 35322193. doi:10.1038/s41379-022-01062-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。